FDG PET for Giant Cavernous Hemangioma Important Clue to Differentiate From a Malignant Vascular Tumor in the LiverShimada, Kotaro, MD; Nakamoto, Yuji, MD, PhD; Isoda, Hiroyoshi, MD, PhD; Saito, Hiromi, MD; Arizono, Shigeki, MD; Shibata, Toshiya, MD, PhD; Togashi, Kaori, MD, PhDClinical Nuclear Medicine: December 2010 - Volume 35 - Issue 12 - p 924-926 doi: 10.1097/RLU.0b013e3181f9de11 Original Article Buy Abstract Author InformationAuthors Article MetricsMetrics Giant cavernous hemangioma of the liver sometimes has a very inhomogeneous appearance with intratumoral degeneration on computed tomography or magnetic resonance imaging, and may mimic a malignant hepatic tumor, including angiosarcoma. There are many reports about F-18 fluorodeoxyglucose (FDG) uptake of angiosarcoma; however, knowledge regarding positron emission tomography findings with FDG for giant hepatic cavernous hemangioma is still limited. We herein present 2 cases of giant hepatic cavernous hemangioma in which low FDG uptake was considered helpful to differentiate from malignant hepatic tumor. From the Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. Received for publication March 4, 2010; accepted March 23, 2010. Reprints: Kotaro Shimada, MD, Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606–8507, Japan. E-mail: email@example.com. Copyright © 2010 Wolters Kluwer Health, Inc. All rights reserved.